Swiss pharmaceutical company Lonza has announced on June 2, that it has expanded its collaboration with biotech company Moderna.

This comes after the announcement of a 10-year strategic collaboration agreement signed between both companies in May 2020 to enable the manufacture of the Moderna Covid-19 vaccine and additional Moderna products in future.

The expanded partnership will see Lonza extending the manufacturing of the drug substance for the Covid-19 vaccine by Moderna. It will also include the installation of a new manufacturing line for the production of drug substances at Lonza’s site in Geleen.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook